Novartis saw its sales rise 2% in the third quarter, thanks to steady overall growth in its innovative medicines division, and a strong 7% increase from its Alcon eye division.
AstraZeneca has joined other financial backers to raise $200 million in funding for ADC Therapeutics, a Swiss-headquartered specialist in antibody drug conjugates (ADCs).
